Patents Represented by Attorney Ron Levy
-
Patent number: 6096753Abstract: Selected novel substituted pyrimidinone and pyridone compounds are effective for prophylaxis and treatment of diseases, such as TNF-.alpha., IL-1.beta., IL-6 and/or IL-8 mediated diseases, and other maladies, such as pain and diabetes. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving inflammation, pain, diabetes and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.Type: GrantFiled: December 4, 1997Date of Patent: August 1, 2000Assignee: Amgen Inc.Inventors: Ulrike D. Spohr, Michael J. Malone, Nathan B. Mantlo
-
Patent number: 6022884Abstract: Selected novel substituted pyridine compounds are effective for prophylaxis and treatment of diseases, such as TNF-.alpha., IL-1.beta., IL-6 and/or IL-8 mediated diseases, and other maladies, such as pain and diabetes. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving inflammation, pain, diabetes, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.Type: GrantFiled: November 3, 1998Date of Patent: February 8, 2000Assignee: Amgen Inc.Inventors: Nathan B. Mantlo, Stephen T. Schlachter, John A. Josey
-
Patent number: 5989538Abstract: Mpl ligand analogs having one or more changed glycosylation sites as compared to a naturally occurring mpl ligand sequence of a corresponding number of amino acids are disclosed. The invention also relates to DNA sequences encoding mpl ligand analogs, recombinant plasmids and host cells for analog expression, and therapeutic compositions including such analogs.Type: GrantFiled: September 11, 1997Date of Patent: November 23, 1999Assignee: Amgen Inc.Inventor: Steven G. Elliott
-
Patent number: 5929032Abstract: The survival and proliferation of Schwann cells can be promoted by culturing such cells in the presence of peptides derived from the EGF-like domain of proteins from the NDF/heregulin family. Colon epithelial cells can be stimulated to multiply and differentiate by culturing such cells in the presence of the same peptides.Type: GrantFiled: December 5, 1996Date of Patent: July 27, 1999Assignee: Amgen Inc.Inventors: Josette Fran.cedilla.oise Carnahan, Shinichi Hara, Hsieng Sen Lu, John Philip Mayer, Steven Kiyoshi Yoshinaga
-
Patent number: 5914251Abstract: Polypeptide growth factors, termed PDFs, are described which are derived from placental tissue and promote the proliferation, growth and survival of prostate cells and epithelial cells. Nucleic acid molecules encoding the polypeptides are also described which are useful in recombinant methods for the production of the polypeptides.Type: GrantFiled: October 22, 1996Date of Patent: June 22, 1999Assignee: Amgen Inc.Inventors: Catherine L. Farrell, Francis H. Martin, Rachel Yabkowitz
-
Patent number: 5861315Abstract: Stem cell factor in combination with soluble interleukin-6 receptor, interleukin-6, for gp130 signaling, supports the proliferation, differentiation and terminal maturation of blood cells from normal human hematopoietic multipotential cells.Type: GrantFiled: October 16, 1996Date of Patent: January 19, 1999Assignees: Amgen Inc., Tosoh CorporationInventor: Tatsutoshi Nakahata
-
Patent number: 5830857Abstract: A method is described for the therapeutic use of brain-derived neurotrophic factor (BDNF) to treat epilepsy.Type: GrantFiled: July 14, 1995Date of Patent: November 3, 1998Assignee: Amgen Inc.Inventors: Josette Fran.cedilla.oise Carnahan, Antoine Depaulis, Paul Feltz, Yves Larmet, Christian Marescaux, Hiroyuki Nawa
-
Patent number: 5817784Abstract: Disclosed are DNA and amino acid sequences for a novel polypeptide termed Neuritin which is expressed primarily in selected regions of the brain.Type: GrantFiled: August 9, 1996Date of Patent: October 6, 1998Assignees: Amgen Inc., Yeda Research and Development Co., Ltd.Inventors: Lars Eyde Theill, Gregory Scott Naeve, Yoav Citri, deceased
-
Patent number: 5770203Abstract: The development of subunits and subunit analogs of the cholera exotoxin by recombinant DNA techniques provides vaccine products that can retain their biological activity and immunogenicity, and can confer protection against disease challenge. Genetically-engineered modifications of the subunits result in products that retain immunogenicity, yet are reduced in, or are essentially free of, enzymatic activity associated with toxin reactogenicity.Type: GrantFiled: May 24, 1995Date of Patent: June 23, 1998Assignees: Amgen Inc., University of Southern CaliforniaInventors: W. Neal Burnette, Harvey R. Kaslow
-
Patent number: 5770577Abstract: Derivatives of the neurotrophic factors BDNF and NT-3 have been prepared by attachment of these polypeptides to a water soluble polymer, for instance, polyethylene glycol.Type: GrantFiled: November 14, 1994Date of Patent: June 23, 1998Assignee: Amgen Inc.Inventors: Olaf Boris Kinstler, Qiao Yan
-
Patent number: 5747639Abstract: The present invention relates to a process for purifying polyethylene glycols (PEGs) which utilizes hydrophobic interaction chromatography (HIC) to separate the PEGs based on their size and on their end-group functionality. The purified PEGs can be used to modify biologically active molecules and improve overall production of such molecules.Type: GrantFiled: March 6, 1996Date of Patent: May 5, 1998Assignee: Amgen Boulder Inc.Inventor: James Ervin Seely
-
Patent number: 5714667Abstract: Disclosed is a mouse in which expression of the gene encoding the CTLA-4 receptor is suppressed. Also disclosed is a nucleic acid construct useful in preparing such a mouse, and a cell line containing such construct.Type: GrantFiled: November 6, 1995Date of Patent: February 3, 1998Assignee: Amgen Canada Inc.Inventors: Paul David Waterhouse, Tak Wah Mak
-
Patent number: 5661125Abstract: The invention is to stable compositions of erythropoietin that contain an antimicrobial preservative thereby providing a multi-dose formulation. Preservatives useful in the pharmaceutical compositions of the present invention include benzyl alcohol, parabens, phenol and mixtures thereof. Other additives, including buffers may be included in the composition.Type: GrantFiled: May 24, 1995Date of Patent: August 26, 1997Assignee: AMGEN, Inc.Inventor: Thomas Wayne Strickland
-
Patent number: 5639658Abstract: Provided are methods for fed batch fermentation of cells to produce a compound of interest. Also provided are methods of preparing a compound of interest.Type: GrantFiled: November 30, 1994Date of Patent: June 17, 1997Assignee: Amgen Inc.Inventors: Kenneth Mitchell Drobish, Vasuki Nagaraju Satyagal, Raj Kumar Sachdev